Gossamer Bio vs Ocular Therapeutix
Gossamer Bio and Ocular Therapeutix are similar in size: $48.5m and $52.0m of revenue in their latest fiscal years. Ocular Therapeutix grew faster (-18.5% against -57.7%). Gossamer Bio kept more of each dollar of sales as profit: a net margin of -351.5% against -511.9%.
| Latest fiscal year | Gossamer BioGOSS, 2025 | Ocular TherapeutixOCUL, 2025 |
|---|---|---|
| Revenue | $48.5m | $52.0m |
| Revenue growth | -57.7% | -18.5% |
| Net income | −$170m | −$266m |
| Operating margin | -352.2% | -519.8% |
| Net margin | -351.5% | -511.9% |
| Return on equity | — | -54.9% |
| Free cash flow | −$171m | −$217m |
| Cash | $37.7m | $737m |
| Total debt | $0 | $71.3m |
| Debt to equity | — | 10.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 161 | 325 |
| Market value | $4.41bn | $1.52bn |
| Price vs our value range | — | — |
| Moat score | — | 17 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 29 sales |